Opendata, web and dolomites

miRCaP SIGNED

Innovative nanoparticle formulation for a miR-133 based treatment of cardiac hypertrophy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 miRCaP project word cloud

Explore the words cloud of the miRCaP project. It provides you a very rough idea of what is the project "miRCaP" about.

efficiency    mortality    patient    govern    nanoparticle    individual    ca    nps    50    ischemic    mir    efficient    multiple    functionalize    etiologies    toxic    formulation    specificity    cell    phosphate       hypertrophy    stress    innovative    cap    capitalist    attracted    found    inflammatory    preventing    strategies    cardiac    strategic    release    remarkable    inversely    pathological    diagnosis    preclinical    structural    calcium    nanoparticles    drugs    commercial    intellectual    strategy    biocompatible    selectively    causes    germane    contraction    business    outcome    unexpected    micrornas    toxicity    therapeutic    np    bioresorbable    candidates    remodeling    dysregulations    identification    venture    defects    failing    successful    proof    additional    post    muscle    genes    cds    diseases    relies    line    worldwide    mir133    generate    heart    population    paid    translation    cardiovascular    roles    genetic    selective    ing    levels    pathogenesis    drug    players    regulate    treatment    unveiled    133    microrna   

Project "miRCaP" data sheet

The following table provides information about the project.

Coordinator
HUMANITAS MIRASOLE SPA 

Organization address
address: VIA MANZONI 56
city: ROZZANO (MI)
postcode: 20100
website: www.humanitas.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2018-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HUMANITAS MIRASOLE SPA IT (ROZZANO (MI)) coordinator 150˙000.00

Map

 Project objective

Innovative nanoparticle formulation for a miR-133 based treatment of cardiac hypertrophy

Cardiovascular diseases (CDs) are growing problems worldwide, affecting as much as 1% of the population. The causes include ischemic, toxic, genetic, post-inflammatory and structural defects; often multiple etiologies are present within an individual patient germane to the contraction failing, resulting in a mortality of ca. 50% within 5 years from diagnosis. Unexpected roles have been unveiled for microRNAs, important key-players in such pathogenesis, able to regulate levels of genes that govern cell remodeling. In line with this, development of microRNA-based drugs aimed at preventing stress-induced dysregulations of microRNA levels has attracted remarkable attention as potential candidates for therapeutic applications. Particular attention is paid to the miR-133, a muscle-specific microRNA, which has been found inversely related to pathological cardiac hypertrophy. However, a key challenge of microRNA-based drugs relies on delivery efficiency, toxicity and specificity. Here, we propose to generate innovative and effective therapeutic strategies based on the development of novel biocompatible and bioresorbable calcium phosphate nanoparticles (CaP-NP) for carrying miR-133 selectively to the heart. Our aim is to functionalize CaP-NPs for a selective delivery of the therapeutic miR133 to the pathological heart. The development of a novel approach based on CaP-NPs might be an efficient cardiac drug-delivery system for a specific release of miR-133. The successful outcome of this proposal will provide a relevant preclinical proof-of-concept necessary for 1) the development of additional Intellectual Properties, 2) the translation into a commercial strategy and business case, and 3) the identification of strategic partners and venture capitalist.

 Publications

year authors and title journal last update
List of publications.
2018 Irene Salamon, Gloria Saccani Jotti, Gianluigi Condorelli
The long noncoding RNA landscape in cardiovascular disease
published pages: 1, ISSN: 0268-4705, DOI: 10.1097/HCO.0000000000000507
Current Opinion in Cardiology 2019-06-13
2018 Serge Masson, Sandor Batkai, Julia Beermann, Christian Bär, Angelika Pfanne, Sabrina Thum, Michela Magnoli, Giovanna Balconi, Gian Luigi Nicolosi, Luigi Tavazzi, Roberto Latini, Thomas Thum
Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure
published pages: 78-85, ISSN: 1388-9842, DOI: 10.1002/ejhf.961
European Journal of Heart Failure 20/1 2019-06-13
2017 Roberto Papait, Simone Serio, Christina Pagiatakis, Francesca Rusconi, Pierluigi Carullo, Marta Mazzola, Nicolò Salvarani, Michele Miragoli, Gianluigi Condorelli
Histone Methyltransferase G9a Is Required for Cardiomyocyte Homeostasis and Hypertrophy
published pages: 1233-1246, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.117.028561
Circulation 136/13 2019-06-13
2017 Veronica Larcher, Paolo Kunderfranco, Marco Vacchiano, Pierluigi Carullo, Marco Erreni, Irene Salamon, Federico Simone Colombo, Enrico Lugli, Marta Mazzola, Achille Anselmo, Gianluigi Condorelli
An autofluorescence-based method for the isolation of highly purified ventricular cardiomyocytes
published pages: 409-416, ISSN: 0008-6363, DOI: 10.1093/cvr/cvx239
Cardiovascular Research 114/3 2019-06-13
2018 Leonardo Elia, Paolo Kunderfranco, Pierluigi Carullo, Marco Vacchiano, Floriana Maria Farina, Ignacio Fernando Hall, Stefano Mantero, Cristina Panico, Roberto Papait, Gianluigi Condorelli, Manuela Quintavalle
UHRF1 epigenetically orchestrates smooth muscle cell plasticity in arterial disease
published pages: 2473-2486, ISSN: 0021-9738, DOI: 10.1172/JCI96121
Journal of Clinical Investigation 128/6 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIRCAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIRCAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

QUAHQ (2019)

PROBING EXOTIC QUANTUM HALL STATES WITH HEAT QUANTUM TRANSPORT

Read More  

T-NHL SUPRESSORS (2019)

Tumor suppressor pathways counteracting oncogenic immune receptor signaling in T-Cell Lymphoma

Read More  

CITISENSE (2019)

Evolving communication systems in response to altered sensory environments

Read More